로딩 중…
지수 로딩 중…
인벤티지랩
389470· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩42,300-2.42%
2026-06-19
Price Chart
인벤티지랩-1.17%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 562.92B KRW |
| Revenue | 3.16B KRW |
| Net Income | -6.83B KRW |
| Total Assets | 214.77B KRW |
| Net Assets | 115.04B KRW |
| Employees | 69 |
| Value | |
| P/B | 4.89x |
| P/S | 178.00x |
| FCF Yield | -3.68% |
| Profitability | |
| ROE | -5.93% |
| ROA | -3.18% |
| Op. Margin | -992.67% |
| Revenue Growth | 132.26% |
| Financial Health | |
| Debt Ratio | 186.70% |
| Total Debt | 28.21B KRW |
| FCF | -20.70B KRW |
| Cash | 107.12B KRW |
| Current Ratio | 2.34x |
| Performance | |
| 1Y Return | -1.17% |
| 1M Return | -12.06% |
| From 52W High | -58.41% |
| 1Y MDD | -58.44% |
| Trading | |
| Volume | 121,932 shares |
| Foreign Own. | 9.34% |
| Per Share | |
| EPS | 225 KRW |
| BPS | 6,527 KRW |
Company Info
Inventis Lab was established in 2015, and in 2025, it acquired KOSDAQ-listed Curatis, securing a mass production base for long-acting injectable drugs and gene therapy/mRNA vaccines. It possesses an IVL platform that applies microfluidic technology to drug research and development, providing long-acting injectable drug development and LNP manufacturing services. The company has license agreements with domestic and international pharmaceutical companies and is expanding clinical trial material production and CDMO business through manufacturing facilities in Curatis' GMP factory. Inventis Lab is headquartered in Seongnam-si, Gyeonggi-do.